1.1 Research Scope 1.2 Market Segmentation 1.3 Research Objectives 1.4 Research Methodology 1.4.1 Research Process 1.4.2 Data Triangulation 1.4.3 Research Approach 1.4.4 Base Year 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.5.2 Covid-19 Impact: Commodity Prices Indices 1.5.3 Covid-19 Impact: Global Major Government Policy 1.6 The Covid-19 Impact on Rare Disease Drug Industry 1.7 COVID-19 Impact: Rare Disease Drug Market Trends 2 Global Rare Disease Drug Quarterly Market Size Analysis 2.1 Rare Disease Drug Business Impact Assessment - COVID-19 2.1.1 Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.1.2 Global Rare Disease Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.2 Global Rare Disease Drug Quarterly Market Size 2020-2021 2.3 COVID-19-Driven Market Dynamics and Factor Analysis 2.3.1 Drivers 2.3.2 Restraints 2.3.3 Opportunities 2.3.4 Challenges 3 Quarterly Competitive Assessment, 2020 3.1 Global Rare Disease Drug Quarterly Market Size by Manufacturers, 2019 VS 2020 3.2 Global Rare Disease Drug Factory Price by Manufacturers 3.3 Location of Key Manufacturers Rare Disease Drug Manufacturing Factories and Area Served 3.4 Date of Key Manufacturers Enter into Rare Disease Drug Market 3.5 Key Manufacturers Rare Disease Drug Product Offered 3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Rare Disease Drug Segments, By Type 4.1 Introduction 1.4.1 Above 1‰ 1.4.2 0.65‰～1‰ 1.4.3 Below 0.1‰ 4.2 By Type, Global Rare Disease Drug Market Size, 2019-2021 4.2.1 By Type, Global Rare Disease Drug Market Size by Type, 2020-2021 4.2.2 By Type, Global Rare Disease Drug Price, 2020-2021 5 Impact of Covid-19 on Rare Disease Drug Segments, By Application 5.1 Overview 5.5.1 Hospital Pharmacies 5.5.2 Speciality Pharmacies 5.5.3 Retail pharmacies 5.5.4 Others 5.2 By Application, Global Rare Disease Drug Market Size, 2019-2021 5.2.1 By Application, Global Rare Disease Drug Market Size by Application, 2019-2021 5.2.2 By Application, Global Rare Disease Drug Price, 2020-2021 6 Geographic Analysis 6.1 Introduction 6.2 North America 6.2.1 Macroeconomic Indicators of US 6.2.2 US 6.2.3 Canada 6.3 Europe 6.3.1 Macroeconomic Indicators of Europe 6.3.2 Germany 6.3.3 France 6.3.4 UK 6.3.5 Italy 6.4 Asia-Pacific 6.4.1 Macroeconomic Indicators of Asia-Pacific 6.4.2 China 6.4.3 Japan 6.4.4 South Korea 6.4.5 India 6.4.6 ASEAN 6.5 Rest of World 6.5.1 Latin America 6.5.2 Middle East and Africa 7 Company Profiles 7.1 Novartis AG 7.1.1 Novartis AG Business Overview 7.1.2 Novartis AG Rare Disease Drug Quarterly Production and Revenue, 2020 7.1.3 Novartis AG Rare Disease Drug Product Introduction 7.1.4 Novartis AG Response to COVID-19 and Related Developments 7.2 Bristol-Myers Squibb Company 7.2.1 Bristol-Myers Squibb Company Business Overview 7.2.2 Bristol-Myers Squibb Company Rare Disease Drug Quarterly Production and Revenue, 2020 7.2.3 Bristol-Myers Squibb Company Rare Disease Drug Product Introduction 7.2.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments 7.3 Celgene Corporation 7.3.1 Celgene Corporation Business Overview 7.3.2 Celgene Corporation Rare Disease Drug Quarterly Production and Revenue, 2020 7.3.3 Celgene Corporation Rare Disease Drug Product Introduction 7.3.4 Celgene Corporation Response to COVID-19 and Related Developments 7.4 F. Hoffmann-La Roche Ltd. 7.4.1 F. Hoffmann-La Roche Ltd. Business Overview 7.4.2 F. Hoffmann-La Roche Ltd. Rare Disease Drug Quarterly Production and Revenue, 2020 7.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Introduction 7.4.4 F. Hoffmann-La Roche Ltd. Response to COVID-19 and Related Developments 7.5 Pfizer, Inc. 7.5.1 Pfizer, Inc. Business Overview 7.5.2 Pfizer, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020 7.5.3 Pfizer, Inc. Rare Disease Drug Product Introduction 7.5.4 Pfizer, Inc. Response to COVID-19 and Related Developments 7.6 Sanofi S.A. 7.6.1 Sanofi S.A. Business Overview 7.6.2 Sanofi S.A. Rare Disease Drug Quarterly Production and Revenue, 2020 7.6.3 Sanofi S.A. Rare Disease Drug Product Introduction 7.6.4 Sanofi S.A. Response to COVID-19 and Related Developments 7.7 Alexion Pharmaceuticals, Inc. 7.7.1 Alexion Pharmaceuticals, Inc. Business Overview 7.7.2 Alexion Pharmaceuticals, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020 7.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Introduction 7.7.4 Alexion Pharmaceuticals, Inc. Response to COVID-19 and Related Developments 7.8 Eli Lilly and Company 7.8.1 Eli Lilly and Company Business Overview 7.8.2 Eli Lilly and Company Rare Disease Drug Quarterly Production and Revenue, 2020 7.8.3 Eli Lilly and Company Rare Disease Drug Product Introduction 7.8.4 Eli Lilly and Company Response to COVID-19 and Related Developments 7.9 Novo Nordisk A/S 7.9.1 Novo Nordisk A/S Business Overview 7.9.2 Novo Nordisk A/S Rare Disease Drug Quarterly Production and Revenue, 2020 7.9.3 Novo Nordisk A/S Rare Disease Drug Product Introduction 7.9.4 Novo Nordisk A/S Response to COVID-19 and Related Developments 7.10 AstraZeneca 7.10.1 AstraZeneca Business Overview 7.10.2 AstraZeneca Rare Disease Drug Quarterly Production and Revenue, 2020 7.10.3 AstraZeneca Rare Disease Drug Product Introduction 7.10.4 AstraZeneca Response to COVID-19 and Related Developments 7.11 Eisai Co., Ltd. 7.11.1 Eisai Co., Ltd. Business Overview 7.11.2 Eisai Co., Ltd. Rare Disease Drug Quarterly Production and Revenue, 2020 7.11.3 Eisai Co., Ltd. Rare Disease Drug Product Introduction 7.11.4 Eisai Co., Ltd. Response to COVID-19 and Related Developments 7.12 Daiichi Sankyo Company Limited 7.12.1 Daiichi Sankyo Company Limited Business Overview 7.12.2 Daiichi Sankyo Company Limited Rare Disease Drug Quarterly Production and Revenue, 2020 7.12.3 Daiichi Sankyo Company Limited Rare Disease Drug Product Introduction 7.12.4 Daiichi Sankyo Company Limited Response to COVID-19 and Related Developments 7.13 Bayer AG 7.13.1 Bayer AG Business Overview 7.13.2 Bayer AG Rare Disease Drug Quarterly Production and Revenue, 2020 7.13.3 Bayer AG Rare Disease Drug Product Introduction 7.13.4 Bayer AG Response to COVID-19 and Related Developments 7.14 GlaxoSmithKline 7.14.1 GlaxoSmithKline Business Overview 7.14.2 GlaxoSmithKline Rare Disease Drug Quarterly Production and Revenue, 2020 7.14.3 GlaxoSmithKline Rare Disease Drug Product Introduction 7.14.4 GlaxoSmithKline Response to COVID-19 and Related Developments 7.15 Merck & Co., Inc. 7.15.1 Merck & Co., Inc. Business Overview 7.15.2 Merck & Co., Inc. Rare Disease Drug Quarterly Production and Revenue, 2020 7.15.3 Merck & Co., Inc. Rare Disease Drug Product Introduction 7.15.4 Merck & Co., Inc. Response to COVID-19 and Related Developments 7.16 Johnson & Johnson 7.16.1 Johnson & Johnson Business Overview 7.16.2 Johnson & Johnson Rare Disease Drug Quarterly Production and Revenue, 2020 7.16.3 Johnson & Johnson Rare Disease Drug Product Introduction 7.16.4 Johnson & Johnson Response to COVID-19 and Related Developments 7.17 Biogen, Inc. 7.17.1 Biogen, Inc. Business Overview 7.17.2 Biogen, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020 7.17.3 Biogen, Inc. Rare Disease Drug Product Introduction 7.17.4 Biogen, Inc. Response to COVID-19 and Related Developments 7.18 Takeda 7.18.1 Takeda Business Overview 7.18.2 Takeda Rare Disease Drug Quarterly Production and Revenue, 2020 7.18.3 Takeda Rare Disease Drug Product Introduction 7.18.4 Takeda Response to COVID-19 and Related Developments 7.19 Amgen, Inc. 7.19.1 Amgen, Inc. Business Overview 7.19.2 Amgen, Inc. Rare Disease Drug Quarterly Production and Revenue, 2020 7.19.3 Amgen, Inc. Rare Disease Drug Product Introduction 7.19.4 Amgen, Inc. Response to COVID-19 and Related Developments 7.20 Deciphera 7.20.1 Deciphera Business Overview 7.20.2 Deciphera Rare Disease Drug Quarterly Production and Revenue, 2020 7.20.3 Deciphera Rare Disease Drug Product Introduction 7.20.4 Deciphera Response to COVID-19 and Related Developments 7.21 Atara Biotherapeutics 7.21.1 Atara Biotherapeutics Business Overview 7.21.2 Atara Biotherapeutics Rare Disease Drug Quarterly Production and Revenue, 2020 7.21.3 Atara Biotherapeutics Rare Disease Drug Product Introduction 7.21.4 Atara Biotherapeutics Response to COVID-19 and Related Developments 7.22 ProQR 7.22.1 ProQR Business Overview 7.22.2 ProQR Rare Disease Drug Quarterly Production and Revenue, 2020 7.22.3 ProQR Rare Disease Drug Product Introduction 7.22.4 ProQR Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis 8.1 Rare Disease Drug Supply Chain Analysis 8.1.1 Rare Disease Drug Supply Chain Analysis 8.1.2 Covid-19 Impact on Rare Disease Drug Supply Chain 8.2 Distribution Channels Analysis 8.2.1 Rare Disease Drug Distribution Channels 8.2.2 Covid-19 Impact on Rare Disease Drug Distribution Channels 8.2.3 Rare Disease Drug Distributors 8.3 Rare Disease Drug Customers 9 Key Findings 10 Appendix 10.1 About Us 10.2 Disclaimer

List of Tables Table 1. Overview of the World Economic Outlook Projections Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity) Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 7. Covid-19 Impact: Global Major Government Policy Table 8. The Covid-19 Impact on Rare Disease Drug Assessment Table 9. COVID-19 Impact: Rare Disease Drug Market Trends Table 10. COVID-19 Impact Global Rare Disease Drug Market Size Table 11. Global Rare Disease Drug Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Doses) Table 12. Global Rare Disease Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Dose) Table 13. Global Rare Disease Drug Quarterly Market Size, 2020 (US$ Million) & (K Doses) Table 14. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million) Table 15. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Doses) Table 16. Global Rare Disease Drug Market Growth Drivers Table 17. Global Rare Disease Drug Market Restraints Table 18. Global Rare Disease Drug Market Opportunities Table 19. Global Rare Disease Drug Market Challenges Table 20. Key Manufacturers Rare Disease Drug Quarterly Revenue, 2019 VS 2020 (US$ Million) Table 21. Top Manufacturers, Rare Disease Drug Market Size, 2019 (K Doses) & (US$ Million) Table 22. Rare Disease Drug Factory Price by Manufacturers 2020 (USD/Dose) Table 23. Location of Key Manufacturers Rare Disease Drug Manufacturing Plants Table 24. Key Manufacturers Rare Disease Drug Market Served Table 25. Date of Key Manufacturers Enter into Rare Disease Drug Market Table 26. Key Manufacturers Rare Disease Drug Product Type Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Rare Disease Drug Market Size by Type, 2020, (US$ Million) Table 29. Global Rare Disease Drug Market Size by Type, 2020 (K Doses) Table 30. Global Rare Disease Drug Price: by Type, 2020-2021 (USD/Dose) Table 31. Global Rare Disease Drug Market Size by Application: 2020-2021 (US$ Million) Table 32. Global Rare Disease Drug Market Size by Application, 2020-2021 (K Doses) Table 33. Global Rare Disease Drug Price: by Application, 2020-2021 (USD/Dose) Table 34. Global Rare Disease Drug Market Size by Region, 2019-2021 (US$ Million) Table 35. Global Rare Disease Drug Market Size by Region, 2019-2021 (K Doses) Table 36. By Country, North America Rare Disease Drug Market Size, 2019-2021 (US$ Million) Table 37. By Country, North America Rare Disease Drug Market Size, 2019-2021 (K Doses) Table 38. US Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 39. Canada Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy) Table 41. By Country, Europe Rare Disease Drug Market Size, 2019-2021 (US$ Million) Table 42. By Country, Europe Rare Disease Drug Market Size, 2019-2021 (K Doses) Table 43. Germany Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 44. France Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 45. UK Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 46. Italy Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN) Table 48. By Region, Asia-Pacific Rare Disease Drug Market Size, 2019-2021 (US$ Million) Table 49. By Region, Asia-Pacific Rare Disease Drug Market Size, 2019-2021 (K Doses) Table 50. China Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 51. Japan Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 52. South Korea Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 53. India Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 54. ASEAN Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 55. Latin America Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 56. Middle East and Africa Rare Disease Drug Market Size, 2019-2021 (US$ Million) & (K Doses) Table 57. Novartis AG Business Overview Table 58. Novartis AG Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 59. Novartis AG Rare Disease Drug Product Table 60. Novartis AG Response to COVID-19 and Related Developments Table 61. Bristol-Myers Squibb Company Business Overview Table 62. Bristol-Myers Squibb Company Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 63. Bristol-Myers Squibb Company Rare Disease Drug Product Table 64. Bristol-Myers Squibb Company Response to COVID-19 and Related Developments Table 65. Celgene Corporation Business Overview Table 66. Celgene Corporation Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 67. Celgene Corporation Rare Disease Drug Product Table 68. Celgene Corporation Response to COVID-19 and Related Developments Table 69. F. Hoffmann-La Roche Ltd. Business Overview Table 70. F. Hoffmann-La Roche Ltd. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 71. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Table 72. F. Hoffmann-La Roche Ltd. Response to COVID-19 and Related Developments Table 73. Pfizer, Inc. Business Overview Table 74. Pfizer, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 75. Pfizer, Inc. Rare Disease Drug Product Table 76. Pfizer, Inc. Response to COVID-19 and Related Developments Table 77. Sanofi S.A. Business Overview Table 78. Sanofi S.A. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 79. Sanofi S.A. Rare Disease Drug Product Table 80. Sanofi S.A. Response to COVID-19 and Related Developments Table 81. Alexion Pharmaceuticals, Inc. Business Overview Table 82. Alexion Pharmaceuticals, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 83. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Table 84. Alexion Pharmaceuticals, Inc. Response to COVID-19 and Related Developments Table 85. Eli Lilly and Company Business Overview Table 86. Eli Lilly and Company Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 87. Eli Lilly and Company Rare Disease Drug Product Table 88. Eli Lilly and Company Response to COVID-19 and Related Developments Table 89. Novo Nordisk A/S Business Overview Table 90. Novo Nordisk A/S Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 91. Novo Nordisk A/S Rare Disease Drug Product Table 92. Novo Nordisk A/S Response to COVID-19 and Related Developments Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 95. AstraZeneca Rare Disease Drug Product Table 96. AstraZeneca Response to COVID-19 and Related Developments Table 97. Eisai Co., Ltd. Business Overview Table 98. Eisai Co., Ltd. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 99. Eisai Co., Ltd. Rare Disease Drug Product Table 100. Eisai Co., Ltd. Response to COVID-19 and Related Developments Table 101. Daiichi Sankyo Company Limited Business Overview Table 102. Daiichi Sankyo Company Limited Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 103. Daiichi Sankyo Company Limited Rare Disease Drug Product Table 104. Daiichi Sankyo Company Limited Response to COVID-19 and Related Developments Table 105. Bayer AG Business Overview Table 106. Bayer AG Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 107. Bayer AG Rare Disease Drug Product Table 108. Bayer AG Response to COVID-19 and Related Developments Table 109. GlaxoSmithKline Business Overview Table 110. GlaxoSmithKline Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 111. GlaxoSmithKline Rare Disease Drug Product Table 112. GlaxoSmithKline Response to COVID-19 and Related Developments Table 113. Merck & Co., Inc. Business Overview Table 114. Merck & Co., Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 115. Merck & Co., Inc. Rare Disease Drug Product Table 116. Merck & Co., Inc. Response to COVID-19 and Related Developments Table 117. Johnson & Johnson Business Overview Table 118. Johnson & Johnson Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 119. Johnson & Johnson Rare Disease Drug Product Table 120. Johnson & Johnson Response to COVID-19 and Related Developments Table 121. Biogen, Inc. Business Overview Table 122. Biogen, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 123. Biogen, Inc. Rare Disease Drug Product Table 124. Biogen, Inc. Response to COVID-19 and Related Developments Table 125. Takeda Business Overview Table 126. Takeda Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 127. Takeda Rare Disease Drug Product Table 128. Takeda Response to COVID-19 and Related Developments Table 129. Amgen, Inc. Business Overview Table 130. Amgen, Inc. Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 131. Amgen, Inc. Rare Disease Drug Product Table 132. Amgen, Inc. Response to COVID-19 and Related Developments Table 133. Deciphera Business Overview Table 134. Deciphera Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 135. Deciphera Rare Disease Drug Product Table 136. Deciphera Response to COVID-19 and Related Developments Table 137. Atara Biotherapeutics Business Overview Table 138. Atara Biotherapeutics Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 139. Atara Biotherapeutics Rare Disease Drug Product Table 140. Atara Biotherapeutics Response to COVID-19 and Related Developments Table 141. ProQR Business Overview Table 142. ProQR Rare Disease Drug Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 143. ProQR Rare Disease Drug Product Table 144. ProQR Response to COVID-19 and Related Developments Table 145. Rare Disease Drug Distributors List Table 146. Rare Disease Drug Customers List Table 147. Covid-19 Impact on Rare Disease Drug Customers List of Figures Figure 1. Rare Disease Drug Product Picture Figure 2. Rare Disease Drug Market Segmentation Figure 3. Research Objectives Figure 4. Research Process Figure 5. Data Triangulation Figure 6. Research Approach Figure 7. Commodity Prices-Metals Price Indices Figure 8. Commodity Prices- Precious Metal Price Indices Figure 9. Commodity Prices- Agricultural Raw Material Price Indices Figure 10. Commodity Prices- Food and Beverage Price Indices Figure 11. Commodity Prices- Fertilizer Price Indices Figure 12. Commodity Prices- Energy Price Indices Figure 13. G20+: Economic Policy Responses to COVID-19 Figure 14. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million) Figure 15. Global Rare Disease Drug Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%) Figure 16. Global Rare Disease Drug Market Size, Quarterly Growth, 2020-2021 (%) Figure 17. Global Rare Disease Drug Market Size, Market Share by Type, 2019 VS 2020 (%) Figure 18. Global Rare Disease Drug Market Size, Market Share by Application, 2019 VS 2020 (%) Figure 19. Global Rare Disease Drug Market Size Market Share by Region, 2019 VS 2020 (%) Figure 20. United States Composite PMI and GDP Figure 21. Eurozone Composite PMI and GDP Figure 22. Eurozone Core v. Periphery PMI Output Indices Figure 23. Core v. Periphery PMI Employment Indices Figure 24. UK Composite PMI and GDP Figure 25. Caixin China Composite Output Index Figure 26. Caixin China General Services Business Activity Index Figure 27. Japan Composite Output Index Figure 28. South Korea Manufacturing PMI Figure 29. India Composite Output Index Figure 30. ASEAN Manufacturing PMI Figure 31. By Region, Asia-Pacific Rare Disease Drug Market Size Market Share, 2019-2021

Novartis AG Bristol-Myers Squibb Company Celgene Corporation F. Hoffmann-La Roche Ltd. Pfizer, Inc. Sanofi S.A. Alexion Pharmaceuticals, Inc. Eli Lilly and Company Novo Nordisk A/S AstraZeneca Eisai Co., Ltd. Daiichi Sankyo Company Limited Bayer AG GlaxoSmithKline Merck & Co., Inc. Johnson & Johnson Biogen, Inc. Takeda Amgen, Inc. Deciphera Atara Biotherapeutics ProQR